Thiazolidinedione Use , Fluid Retention , and Congestive Heart Failure A consensus statement from the American Heart Association and American Diabetes Association

@inproceedings{Nesto2003ThiazolidinedioneU,
  title={Thiazolidinedione Use , Fluid Retention , and Congestive Heart Failure A consensus statement from the American Heart Association and American Diabetes Association},
  author={Richard W. Nesto and David W. Bell and Robert Ogden Bonow and Vivian Fonseca and Scott M Grundy and Edward S. Horton and Martin Le Winter and Daniel Porte and Clay F Semenkovich and Sidney C. Smith and Lawrence H. Young and Richard Kahn},
  year={2003}
}
D iabetes is a chronic, progressively worsening disease associated with a variety of microvascular and macrovascular complications. Cardiovascular disease (CVD) is the main cause of death in these patients (1,2). During the past decade, numerous drugs have been introduced for the treatment of type 2 diabetes that, used in monotherapy or in combination therapy, are effective in lowering blood glucose to achieve glycemic goals and in reducing diabetes-related endorgan disease. Two such drugs… CONTINUE READING